Trial Profile
Long-term safety and tolerability of REGN727/SAR236553 in High Cardiovascular Risk Patients with Hypercholesterolemia not adequately controlled with their lipid modifying therapy: a randomized, double-blind, placebo-controlled study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Jan 2022
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary) ; Atorvastatin; Rosuvastatin; Simvastatin
- Indications Atherosclerosis; Cardiovascular disorders; Hypercholesterolaemia; Hyperlipoproteinaemia type IIa
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms LONG-TERM; ODYSSEY-LONG-TERM
- Sponsors Sanofi
- 17 Oct 2021 Results of Meta-Analysis from eight randomized, double-blind, placebo-controlled studies assessing Clinical Outcomes of PCSK9 Modulators in Patients with Established ASCVD published in the Pharmacotherapy
- 05 Sep 2018 Results of pooled data from 14 trials, were published in the Diabetic Medicine.
- 01 Jun 2018 Results of a pooled analysis of 5 studies (LONG TERM, HIGH FH, FH I, FH II and COMBO) assessing the safety and efficacy of Alirocumab, published in the Diabetes Therapy